Open | - |
Close | - |
Volume / Avg. | 99.000 / 1.130M |
Day Range | - - - |
52 Wk Range | 215.350 - 334.580 |
Market Cap | $31.892B |
P/E Ratio | 27.528 |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 40 |
Short Interest | 2.4% |
Days to Cover | 2.46 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Biogen (NASDAQ: BIIB) through any online brokerage.
Other companies in Biogen’s space includes: Legend Biotech (NASDAQ:LEGN), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX) and Cerevel Therapeutics Hldg (NASDAQ:CERE).
The latest price target for Biogen (NASDAQ: BIIB) was reported by RBC Capital on Tuesday, March 5, 2024. The analyst firm set a price target for 364.00 expecting BIIB to rise to within 12 months (a possible 65.91% upside). 86 analyst firms have reported ratings in the last year.
The stock price for Biogen (NASDAQ: BIIB) is $219.4 last updated March 18, 2024 at 4:04 PM EDT.
There are no upcoming dividends for Biogen.
Biogen’s Q1 earnings are confirmed for Tuesday, April 23, 2024.
There is no upcoming split for Biogen.
Biogen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.